Farxiga: Uses, Dosage, Side Effects Warnings - Drugs. com Farxiga (dapagliflozin) is an oral prescription medication that may be given to certain adults with diabetes, heart disease, or kidney disease to improve their outcomes It may also be given to children aged 10 years and older with type 2 diabetes
Farxiga (dapagliflozin) - Uses, Side Effects, and More - WebMD Farxiga is also used in people with chronic (long-term) kidney disease, heart failure, or type 2 diabetes and heart disease (or at high risk for heart disease) to prevent the following complications
Dapagliflozin (oral route) - Side effects dosage - Mayo Clinic Dapagliflozin does not help patients who have insulin-dependent or type 1 diabetes Type 1 diabetic patients must use insulin injections Dapagliflozin is also used to lower the risk of hospitalization for heart failure in patients with type 2 diabetes and cardiovascular (heart or blood vessel) disease or multiple cardiovascular risk factors
Farxiga (Dapagliflozin): Uses, Side Effects, Dosage More - GoodRx Farxiga, the brand name for dapagliflozin, is used together with a nutritious diet and exercise plan to lower blood sugar levels in people 10 years and older with Type 2 diabetes It can also help lower the risk of serious complications, hospitalization, and death in certain adults with heart failure or chronic kidney disease (CKD) Farxiga (dapagliflozin) belongs to the drug class called
Dapagliflozin: MedlinePlus Drug Information Dapagliflozin is used to lower blood sugar in people with type 2 diabetes (condition in which blood sugar is too high because the body does not make or use insulin normally) to reduce the risk of being hospitalized for heart failure in certain adults with type 2 diabetes to reduce the risk of being hospitalized for heart failure and death in adults with heart failure to reduce the risk of
AstraZeneca lands OPDP untitled letter over Farxiga TV ad The US Food and Drug Administration (FDA) on Monday published an untitled letter it sent to AstraZeneca on 23 September concerning a TV commercial for its drug Farxiga (dapagliflozin) @ Regulators claimed that the company failed to fully disclose the endpoints used to approve the drug in the 45-second ad